These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 24245758

  • 1. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
    Bueno RV, Braga RC, Segretti ND, Ferreira EI, Trossini GH, Andrade CH.
    Curr Pharm Des; 2014; 20(27):4474-85. PubMed ID: 24245758
    [Abstract] [Full Text] [Related]

  • 2. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H.
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [Abstract] [Full Text] [Related]

  • 3. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.
    Rajkhowa S, Deka RC.
    Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759
    [Abstract] [Full Text] [Related]

  • 4. Mechanistic investigation of resistance via drug-inactivating enzymes in Mycobacterium tuberculosis.
    Kashyap A, Singh PK, Silakari O.
    Drug Metab Rev; 2018 Nov; 50(4):448-465. PubMed ID: 30343607
    [Abstract] [Full Text] [Related]

  • 5. It is anticipated that as is usually the case, financial motivation will move TZ from its current status “potential anti-MDR/XDR agent,” to one that will cure MDR and XDR TB. Foreword.
    Amaral L.
    Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):76. PubMed ID: 21796848
    [No Abstract] [Full Text] [Related]

  • 6. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.
    Lohrasbi V, Talebi M, Bialvaei AZ, Fattorini L, Drancourt M, Heidary M, Darban-Sarokhalil D.
    Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117
    [Abstract] [Full Text] [Related]

  • 7. Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1.
    Lee H, Suh JW.
    J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):205-12. PubMed ID: 26586403
    [Abstract] [Full Text] [Related]

  • 8. Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-resistant Mycobacterium tuberculosis isolates.
    Horita Y, Takii T, Yagi T, Ogawa K, Fujiwara N, Inagaki E, Kremer L, Sato Y, Kuroishi R, Lee Y, Makino T, Mizukami H, Hasegawa T, Yamamoto R, Onozaki K.
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4140-5. PubMed ID: 22615274
    [Abstract] [Full Text] [Related]

  • 9. New treatment options for multidrug-resistant tuberculosis.
    Field SK, Fisher D, Jarand JM, Cowie RL.
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [Abstract] [Full Text] [Related]

  • 10. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
    Martins F, Ventura C, Santos S, Viveiros M.
    Curr Pharm Des; 2014 Oct; 20(27):4427-54. PubMed ID: 24245762
    [Abstract] [Full Text] [Related]

  • 11. Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: an update.
    Chaiprasert A, Srimuang S, Tingtoy N, Makhao N, Sirirudeeporn P, Tomnongdee N, Theankeaw O, Charoensook S, Leechawengwongs M, Prammananan T.
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):961-3. PubMed ID: 25199012
    [Abstract] [Full Text] [Related]

  • 12. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
    Chen J, Peng P, Du Y, Ren Y, Chen L, Rao Y, Wang W.
    BMC Infect Dis; 2017 Apr 24; 17(1):300. PubMed ID: 28438132
    [Abstract] [Full Text] [Related]

  • 13. Extensively drug-resistant tuberculosis: new strains, new challenges.
    Banerjee R, Schecter GF, Flood J, Porco TC.
    Expert Rev Anti Infect Ther; 2008 Oct 24; 6(5):713-24. PubMed ID: 18847407
    [Abstract] [Full Text] [Related]

  • 14. Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)--a novel, patentable approach to limit the emergence of XDR-TB.
    Martins M.
    Recent Pat Antiinfect Drug Discov; 2011 May 24; 6(2):110-7. PubMed ID: 21517742
    [Abstract] [Full Text] [Related]

  • 15. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
    Pieroni M, Wan B, Zuliani V, Franzblau SG, Costantino G, Rivara M.
    Eur J Med Chem; 2015 Jul 15; 100():44-9. PubMed ID: 26071857
    [Abstract] [Full Text] [Related]

  • 16. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, Koh WJ.
    Clin Infect Dis; 2008 Aug 15; 47(4):496-502. PubMed ID: 18611154
    [Abstract] [Full Text] [Related]

  • 17. Nanocarrier-based interventions for the management of MDR/XDR-TB.
    Mustafa S, Pai RS, Singh G, Kusum Devi V.
    J Drug Target; 2015 May 15; 23(4):287-304. PubMed ID: 25766078
    [Abstract] [Full Text] [Related]

  • 18. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
    Blöndal K, Viiklepp P, Guðmundsson LJ, Altraja A.
    Int J Tuberc Lung Dis; 2012 Sep 15; 16(9):1228-33. PubMed ID: 22748131
    [Abstract] [Full Text] [Related]

  • 19. Current Insights into the Chemistry and Antitubercular Potential of Benzimidazole and Imidazole Derivatives.
    Parwani D, Bhattacharya S, Rathore A, Mallick C, Asati V, Agarwal S, Rajoriya V, Das R, Kashaw SK.
    Mini Rev Med Chem; 2021 Sep 15; 21(5):643-657. PubMed ID: 33138762
    [Abstract] [Full Text] [Related]

  • 20. Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
    Reddy DS, Kongot M, Kumar A.
    Tuberculosis (Edinb); 2021 Mar 15; 127():102050. PubMed ID: 33540334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.